Nama's AI scorecard currently rates IDEAYA Biosciences Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does IDYA report earnings?

IDEAYA Biosciences's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$1.16.

What is the IDYA price target?

The median analyst price target from 13 analysts is $51.00, with a range of $30.00 – $66.00.

Is IDYA Shariah compliant?

Nama's AAOIFI-style screen reads IDEAYA Biosciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

IDEAYA Biosciences (IDYA)

Healthcare · Biotechnology · NASDAQ

IDEAYA Biosciences (IDYA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.02B and a free-cash-flow yield of -2.7%. Over the most recent reported fiscal year, revenue grew 3024.4%. Nama's AI scorecard rates it Sell, 2.8 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 2.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Rising · +21.5% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-34.5%

How far the last close sits under the highest price of the past five years.

Market cap	$3.02B
Trailing P/E	—
Price / book	2.5
Price / sales	12.9
FCF yield	-2.7%
Dividend yield	—
Gross margin	-59.8%
Operating margin	-1380.7%
Net margin	-74.8%
Revenue growth (YoY)	+3024.4%
Revenue growth (3-yr annual)	+62.5%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	-0.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

IDYA earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$1.16). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 4, 2026	-$1.22	-$1.05	-16.2%	$8.86M
Q1 2026	May 5, 2026	-$1.11	-$0.98	-13.3%	$6.56M
Q4 2025	Feb 17, 2026	-$0.94	-$0.95	+1.1%	$10.88M
Q3 2025	Nov 4, 2025	$1.33	-$0.55	+341.8%	$207.83M

IDYA analyst price target

Median target $51.00 from 13 analysts, ranging $30.00 – $66.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live IDYA data on Nama Insights →

IDYA FAQ

Is IDYA a buy?: Nama's AI scorecard currently rates IDEAYA Biosciences Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does IDYA report earnings?: IDEAYA Biosciences's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$1.16.
What is the IDYA price target?: The median analyst price target from 13 analysts is $51.00, with a range of $30.00 – $66.00.
Is IDYA Shariah compliant?: Nama's AAOIFI-style screen reads IDEAYA Biosciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.